drugset / Trial / NCT04021992
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of GVD±R (gemcitabine, oral vinorelbine and doxorubicin liposome, with or without rituximab) regimen for autologous hematopoietic stem cell transplantation(ASCT)-eligible patients with refractory/relapsed diffuse large B-cell lymphoma.
Timeline
- Start
- 2019-07-15
- Primary completion
- 2023-07-15
- Completion
- 2023-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 30 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Vinorelbine | Small molecule | 50 mg/m2 | Oral |